Search Results
FDA Approval of Brentuximab Vedotin Plus AVD in Classical Hodgkin Lymphoma
Phase 2 trial of brentuximab vedotin plus AVD for non-bulky limited-stage Hodgkin lymphoma
SWOG S1826: nivolumab+AVD vs brentuximab vedotin+AVD for advanced stage Hodgkin lymphoma
Can A+AVD replace PET-directed strategies for the frontline treatment of Hodgkin lymphoma?
Hodgkin Lymphoma: Upfront Brentuximab Vedotin + AVD
Brentuximab vedotin, nivolumab, doxorubicin & dacarbazine for early stage classical Hodgkin lymphoma
ECHELON-1 study of brentuximab vedotin as frontline therapy for Hodgkin's lymphoma
Brentuximab vedotin for advanced Hodgkin lymphoma in the ECHELON-1 study
A Study of Brentuximab Vedotin and Nivolumab in Relapsed or Treatment-Resistant Hodgkin Lymphoma
Research Builds On Positive ECHELON-1 Study in Hodgkin Lymphoma
Dr. Diefenbach on Ipilimumab/Brentuximab Vedotin in Patients With RR Hodgkin Lymphoma
Dr. Hutchings on the Aim of the ECHELON-1 Study in Hodgkin Lymphoma
